Zhou C, Li X, Wang C, Zhang J. Alopecia areata: an update on etiopathogenesis, diagnosis, and management. Clin Rev Allergy Immunol. 2021;61(3):403–23. https://doi.org/10.1007/s12016-021-08883-0.

Article  PubMed  Google Scholar 

Connell SJ, Jabbari A. The current state of knowledge of the immune ecosystem in alopecia areata. Autoimmun Rev. 2022;21(5): 103061. https://doi.org/10.1016/j.autrev.2022.103061.

Article  CAS  PubMed  PubMed Central  Google Scholar 

King BA, Craiglow BG. Janus kinase inhibitors for alopecia areata. J Am Acad Dermatol. 2023;89(2s):S29-32. https://doi.org/10.1016/j.jaad.2023.05.049.

Article  CAS  PubMed  Google Scholar 

Fung S, Shirley M. Baricitinib: a review in severe alopecia areata. Am J Clin Dermatol. 2023;24(4):661–8. https://doi.org/10.1007/s40257-023-00799-z.

Article  PubMed  Google Scholar 

Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D, et al. Alopecia areata investigational assessment guidelines: Part II. National Alopecia Areata Foundation. J Am Acad Dermatol. 2004;51(3):440–7. https://doi.org/10.1016/j.jaad.2003.09.032.

Article  PubMed  Google Scholar 

Liu LY, Craiglow BG, Dai F, King BA. Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol. 2017;76(1):22–8. https://doi.org/10.1016/j.jaad.2016.09.007.

Article  CAS  PubMed  Google Scholar 

Oba MC, Askin O, Balci Ekmekci O, Serdaroglu S. Correlation between serum granulysin level and clinical activity in patients with alopecia areata before and after tofacitinib therapy. J Cosmet Dermatol. 2021;20(3):971–5. https://doi.org/10.1111/jocd.13598.

Article  PubMed  Google Scholar 

Husein-ElAhmed H, Abdulla N, Al-Obaidli A, Ali-Alam M, Steinhoff M. Real-world experience and long-term evaluation of tofacitinib in refractory alopecia areata: a prospective, open-label, single-center study in Asian Arab population. Dermatol Ther. 2022;35(12): e15871. https://doi.org/10.1111/dth.15871.

Article  CAS  PubMed  Google Scholar 

Wyrwich KW, Kitchen H, Knight S, Aldhouse NVJ, Macey J, Nunes FP, et al. The alopecia areata investigator global assessment scale: a measure for evaluating clinically meaningful success in clinical trials. Br J Dermatol. 2020;183(4):702–9. https://doi.org/10.1111/bjd.18883.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Toussi A, Barton VR, Le ST, Agbai ON, Kiuru M. Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: a systematic review. J Am Acad Dermatol. 2021;85(1):162–75. https://doi.org/10.1016/j.jaad.2020.06.047.

Article  PubMed  Google Scholar 

Phan K, Sebaratnam DF. JAK inhibitors for alopecia areata: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2019;33(5):850–6. https://doi.org/10.1111/jdv.15489.

Article  CAS  PubMed  Google Scholar 

King B, Shapiro J, Ohyama M, Egeberg A, Piraccini BM, Craiglow B, et al. When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials. Br J Dermatol. 2023;189(6):666–73. https://doi.org/10.1093/bjd/ljad253.

Article  PubMed  Google Scholar 

Huang J, Qian P, Tang Y, Li J, Liu F, Shi W. Effectiveness and predictive factors of response to tofacitinib therapy in 125 patients with alopecia areata: a single-centre real-world retrospective study. Acta Derm Venereol. 2023;103:12425. https://doi.org/10.2340/actadv.v103.12425.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kennedy Crispin M, Ko JM, Craiglow BG, Li S, Shankar G, Urban JR, et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight. 2016;1(15): e89776. https://doi.org/10.1172/jci.insight.89776.

Article  PubMed  PubMed Central  Google Scholar 

Park HS, Kim MW, Lee JS, Yoon HS, Huh CH, Kwon O, et al. Oral tofacitinib monotherapy in Korean patients with refractory moderate-to-severe alopecia areata: a case series. J Am Acad Dermatol. 2017;77(5):978–80. https://doi.org/10.1016/j.jaad.2017.06.027.

Article  PubMed  Google Scholar 

AlMarzoug A, AlOrainy M, AlTawil L, AlHayaza G, AlAnazi R, AlIssa A, et al. Alopecia areata and tofacitinib: a prospective multicenter study from a Saudi population. Int J Dermatol. 2022;61(7):886–94. https://doi.org/10.1111/ijd.15917.

Article  CAS  PubMed  Google Scholar 

Ko JM, Mayo TT, Bergfeld WF, Dutronc Y, Yu G, Ball SG, et al. Clinical outcomes for uptitration of baricitinib therapy in patients with severe alopecia areata: a pooled analysis of the BRAVE-AA1 and BRAVE-AA2 trials. JAMA Dermatol. 2023;159(9):970–6. https://doi.org/10.1001/jamadermatol.2023.2581.

Article  PubMed  PubMed Central  Google Scholar 

King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial. Lancet. 2023;401(10387):1518–29. https://doi.org/10.1016/s0140-6736(23)00222-2.

Article  CAS  PubMed  Google Scholar 

Moreno-Vílchez C, Bonfill-Ortí M, Bauer-Alonso A, Notario J, Figueras-Nart I. Baricitinib for the treatment of alopecia areata in adults: real-world analysis of 36 patients. J Am Acad Dermatol. 2024;90(5):1059–61. https://doi.org/10.1016/j.jaad.2023.09.089.

Article  CAS  PubMed  Google Scholar 

Guo L, Feng S, Sun B, Jiang X, Liu Y. Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis. J Eur Acad Dermatol Venereol. 2020;34(1):192–201. https://doi.org/10.1111/jdv.15937.

Article  CAS  PubMed  Google Scholar 

Shin JW, Huh CH, Kim MW, Lee JS, Kwon O, Cho S, et al. Comparison of the treatment outcome of oral tofacitinib with other conventional therapies in refractory alopecia totalis and universalis: a retrospective study. Acta Derm Venereol. 2019;99(1):41–6. https://doi.org/10.2340/00015555-3057.

Article  CAS  PubMed  Google Scholar 

Serdaroğlu S, Engin B, Çelik U, Erkan E, Aşkın Ö, Oba Ç, et al. Clinical experiences on alopecia areata treatment with tofacitinib: a study of 63 patients. Dermatol Ther. 2019;32(3): e12844. https://doi.org/10.1111/dth.12844.

Article  PubMed  Google Scholar 

Yan D, Fan H, Chen M, Xia L, Wang S, Dong W, et al. The efficacy and safety of JAK inhibitors for alopecia areata: a systematic review and meta-analysis of prospective studies. Front Pharmacol. 2022;13: 950450. https://doi.org/10.3389/fphar.2022.950450.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu LY, King BA. Response to tofacitinib therapy of eyebrows and eyelashes in alopecia areata. J Am Acad Dermatol. 2019;80(6):1778–9. https://doi.org/10.1016/j.jaad.2018.11.037.

Article  PubMed  Google Scholar 

Kerkemeyer KLS, John JM, Sinclair R, Bhoyrul B. Response of alopecia areata of the beard to oral tofacitinib. J Am Acad Dermatol. 2020;82(5):1228–30. https://doi.org/10.1016/j.jaad.2019.10.058.

Article  CAS  PubMed  Google Scholar 

Diluvio L, Matteini E, Lambiase S, Cioni A, Gaeta Shumak R, Dattola A, et al. Effect of baricitinib in patients with alopecia areata: usefulness of trichoscopic evaluation. J Eur Acad Dermatol Venereol. 2024;38(6):e478–80. https://doi.org/10.1111/jdv.19663.

Article  CAS  PubMed  Google Scholar 

Waśkiel-Burnat A, Rakowska A, Sikora M, Olszewska M, Rudnicka L. Alopecia areata predictive score: a new trichoscopy-based tool to predict treatment outcome in patients with patchy alopecia areata. J Cosmet Dermatol. 2020;19(3):746–51. https://doi.org/10.1111/jocd.13064.

Article  PubMed  Google Scholar 

Gómez-Quispe H, Muñoz Moreno-Arrones O, Hermosa-Gelbard Á, Vañó-Galván S, Saceda-Corralo D. Trichoscopy in alopecia areata. Actas Dermosifiliogr. 2023;114(1):25–32. https://doi.org/10.1016/j.ad.2022.08.018.

Article  PubMed